Omnicef: profile and news






Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP ...  May 8, 2006
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - PharmaLive.com (press release),

Medicis Reports First Quarter 2006 Financial Results  May 9, 2006
At the end of the March 2006 quarter, the Company's core brands included DYNACIN(R), LOPROX(R), OMNICEF(R), PLEXION(R), RESTYLANE(R), TRIAZ(R) and VANOS(TM). ... - PrimeZone (press release),

Abbott Reports First Quarter Results Led by Strong Medical ...  Apr 19, 2006
17.3)(c) $249 (29.5) Depakote $229 12.0 $17 39.0 $246 13.5 Ultane/Sevorane $82 9.4 $125 2.5 (d) $207 5.2 TriCor $205 20.0 --- -- $205 20.0 Omnicef $143 5.9 ... - MSN Money


Other information


Indication
For the treatment of the following infections (respiratory, skin, soft tissue,ENT) caused by; H.influenzae (including b-lactamase producing strains), H.parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains

Pharmacology
Not Available

Mechanism Of Action
Not Available

Drug Category
Anti-Infectives; ATC:J01DD15

Brand Names/Synonyms
Cefdinir; Cefdinir [Usan:Inn]; Cefdinirum [Inn-Latin]; Cefdinyl; Cefdirnir; Omnicef

Dosage Forms
Not Available

Absorption
Not Available

Interactions
-->Interactions for Cefdinir:

Antacids (aluminum- or magnesium-containing)

Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.

Probenecid

As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.

Iron Supplements and Foods Fortified With Iron

Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.

The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.

Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.

There have been rare reports of reddish stools in patients who have received cefdinir in Japan. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.

Drug/Laboratory Test Interactions

A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest®, Benedictís solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or Tes-Tape®) be used. Cephalosporins are known to occasionally induce a positive direct Coombsí test.



Chemical IUPAC Name
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid

Chemical Formula
C14H13N5O5S2

Half Life
1.7 +/- 0.6 hours

Drug Type
Approved Drug

# Accession No
APRD00644

CAS Registry Number
91832-40-5

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org